{"name":"Comprehensive Support Project for Oncology Research","slug":"comprehensive-support-project-for-oncology-research","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"trastuzumab and chemotherapy","genericName":"trastuzumab and chemotherapy","slug":"trastuzumab-and-chemotherapy","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"trastuzumab monotherapy","genericName":"trastuzumab monotherapy","slug":"trastuzumab-monotherapy","indication":"Adjuvant treatment of HER2-positive breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"trastuzumab and chemotherapy","genericName":"trastuzumab and chemotherapy","slug":"trastuzumab-and-chemotherapy","phase":"phase_3","mechanism":"Trastuzumab blocks HER2 signaling on cancer cells while chemotherapy drugs kill rapidly dividing cells, combining targeted and cytotoxic approaches.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)","HER2-positive gastric cancer"],"catalyst":""},{"name":"trastuzumab monotherapy","genericName":"trastuzumab monotherapy","slug":"trastuzumab-monotherapy","phase":"phase_3","mechanism":"Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.","indications":["Adjuvant treatment of HER2-positive breast cancer","Treatment of HER2-positive metastatic breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOZmkwdFAtSFFXbjlmUkRodUptMzVoZDBDcm55VEN5Yy1oTjFNOFltVE1HQ3pib3dXUXFnanFBOUdKdlFCcDhXcEktZ2YzV1Q0ZDQ0NW1uRUNmNV84QzAyek1iSHJOSHI1WDZ2Y0ZhZXFUbk93T3JWNlZMRnQ4Y05aYlAzalpXNDdrQkFtdmdDcVR1RE1iVFE?oc=5","date":"2025-12-18","type":"regulatory","source":"fda.gov","summary":"List of OCE Programs and Projects - fda.gov","headline":"List of OCE Programs and Projects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNdFZVVkVPZDhHRzJaazZQQnJDYm1VVWtlOElQa056UVZmcHV5STRmaVpVZjkyTS1lWnl6YlFrQXVzajA0dGUxME0zdjVuSG5wbkFXR3h5SUQ3R1NMMl85UmpIaV9LY19NejRlTTZzWDRNVGIxV1hWblloSEl4alRaQTFmcTdlRzM2NV9RNVhmV3ZaMFZpTlJHOVQwVXlvS1U?oc=5","date":"2025-11-21","type":"trial","source":"Applied Clinical Trials","summary":"How the Pharmaceutical Industry Can Work More Effectively with Hospitals to Grow Clinical Trials - Applied Clinical Trials","headline":"How the Pharmaceutical Industry Can Work More Effectively with Hospitals to Grow Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFByYTRac1hvUFNtSHBGQlpiTVJ5N3dVUlp5b1pLTTdabUVEM2tjcndudmN0LVY2d0V5YnlIR3c0NkR3WkhBMlhGVDQ4V25xbExsci1HSjBaWHVyZ3ZOVnpV?oc=5","date":"2025-11-04","type":"trial","source":"Nature","summary":"HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy - Nature","headline":"HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzuma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFAxNGwxUTB0TGdKcUpjX2xWTUJjbXoxQUFIalBwZXl3b0pnNmUzWmJqVG5mMUl1SkdXbXFCYU9BbTYyeTcwbXZZQVpVSTVVWDIxZEZDZk5kejRFNzhsZlFZ?oc=5","date":"2025-10-29","type":"trial","source":"Nature","summary":"Dynamic clinical trial success rates for drugs in the 21st century - Nature","headline":"Dynamic clinical trial success rates for drugs in the 21st century","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9GcVRJM3pobjJmcnNobWVDZEliT1NfNUZfNG9PY1FWMGViWXJKODJCWWVDb3RDWmZiSElhd01Cekc0enhMUnRnX2lsSHd2ZDFsbU1Ncm1aeXlJaVNEV2xn?oc=5","date":"2025-10-24","type":"trial","source":"Nature","summary":"Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey | npj Breast Cancer - Nature","headline":"Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"Taylor & Francis Online","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - Taylor & Francis Online","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQYk82WXJjY0JBdEY4dnRaeUI3eW1MblBOMHJ0aVFEOEE3U3k0dEU4eUo0OWZfVnMxekdfY2RFYzY1bHBxWDFlZGJMZlZRbXpjcUs2cnBVQ242a3ZXUmpXakNLdkRiNFNPenFNS3hZcFU2dDBENTZiWWkybjM3b2xWX0FUcEVJVEFVNFJZMFln?oc=5","date":"2025-09-09","type":"pipeline","source":"Frontiers","summary":"Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody - Frontiers","headline":"Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPUUtPN055RlJsVV9TTzdENV9SMV9WeEVJLS13NzFlQWFOTGc2ZVFBQUJvS0pjVWFGS0VSUF91M2Z2TkdvdDc4eTdnX25XMHpZUVlXelV1cXV6OExsZmUxUVZONDJNWjlWNDBwYzdQUE90WHFMbWRvMnJNSGhrTk1LLXhqMUN3aEpOY2xkOFVoNW1oUjZwY3NfekNRVi11Vm9RaldsaktsbThBc0Z6N0FVbE41bkhMWWdaSXlDNnNGTW43VGIt?oc=5","date":"2025-05-30","type":"regulatory","source":"Fierce Pharma","summary":"ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win - Fierce Pharma","headline":"ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNOXR6dklFNzlzRklKRFJIX19Ia0QyLXp5MzNMWXFRZTRhbGlBRHpLQkJLVUNKNmxGYnJKSmJWcEY0TVk1cTlsWDRia0s5ZUtmcmxKa1NLYmV5RnppZ1pBSlF5SGEwUmRPNjl4ckxadzlVclkzMXdkUk9BMHMwNVlpSzFzVUZBM3FMd21fOFE3dk9KZkN4bUkxbDR1SUpXOHc4cWhxakRwVWdfSnlMRDBBaUtRVnhfZzdsTlNtTU5hdm9XYXlEaXZvMnpTVi03TEc4N2xBbElRZWwyTFVwOTJvYWh3eEJyOTc0VUh3QzlWbHRwOEJWd2c?oc=5","date":"2024-12-05","type":"trial","source":"UNC Gillings School of Global Public Health","summary":"UNC researchers awarded up to $10M to leverage data science to accelerate cancer diagnosis and optimize delivery of precision oncology - UNC Gillings School of Global Public Health","headline":"UNC researchers awarded up to $10M to leverage data science to accelerate cancer diagnosis and optimize delivery of prec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5nekxtUHFNZGRvR0l2SHN5VDcwaVlBd193RUtBN3M0MWNndnAxRmpheVVOYVBwTjM3d0ZCRTJrOVYyZ1FhbEVjMURFdlpWX1RVR2h5VTE5V2YzWXJ6UU9Iam5FMV91Mi1lbEphMVpqSGtBM3RGQkp2UUZR?oc=5","date":"2024-12-04","type":"pipeline","source":"Oncodaily","summary":"100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024 - Oncodaily","headline":"100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOaFdSNDVZMFB4Y3pCYVJkaktjQ28zNzdtNmlOUURzS0RRUW16MGZORm9TOXBlaVoteDNVUWVhTXZnRkhVRkFOLUNkVW1SZk45RmRubjNoN1VSQVFUbnBlVUZEcEMxSUx5ODczNGhfRnJBSTEzQkd6VzNNVkVOS09OcE1vTUhuVDlaZ0RxMzlhb3RySU9DX3VGSG11cG9lMzB2eXR5WHlHWVp5bmhocHlha3c4VUw2SXg5Wlc3ZGdJWnFpVUZtLWdtVFVKMVp5MjU5aUFwU1Vybm1kSzBMYnZoSVVXWVUwWTlOYmd1UktIaWg?oc=5","date":"2024-09-27","type":"pipeline","source":"Empire State Development (ESD) (.gov)","summary":"Empire State Development Announces Opening Of $9 Million Biotech Incubator Harlem Biospace @ Mink In Innovation Triangle-West Harlem | Empire State Development - Empire State Development (ESD) (.gov)","headline":"Empire State Development Announces Opening Of $9 Million Biotech Incubator Harlem Biospace @ Mink In Innovation Triangle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBaa3dJdnRucDhuNGhHWElWbDZJXzhjc19XMlB5bmN4Y3Uzc3ZjVzB2SGJ0aDRsalhJM1A2WDZCLVY2WlRJRGZFaUZtNWdBaURpeEktS2c5Zjh3a1BaVnFQOWFUQUZodFRiNEpJUWUwVzJHNDkwNWlwcFJ4MA?oc=5","date":"2017-01-12","type":"trial","source":"Wiley","summary":"Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Ca","headline":"Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive b","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}